Robotic transanal total mesorectal excision: A new perspective for low rectal cancer treatment. A case series.

Minimally-invasive surgery Rectal cancer Rectal surgery Robotic transanal surgery TME

Journal

International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872

Informations de publication

Date de publication:
2019
Historique:
received: 17 06 2019
revised: 03 07 2019
accepted: 09 07 2019
pubmed: 29 7 2019
medline: 29 7 2019
entrez: 29 7 2019
Statut: ppublish

Résumé

Rectal cancer treatment is still a challenging frontier in general surgery, as there is no general agreement on which surgical approach is best for its management. Total mesorectal excision (TME), influenced the practical approach to rectal cancer, and brought a significant improvement on tumor recurrence and patients survival. Robotic transanal surgery is a newer approach to rectal dissection whose purpose is to overcome the limits of the traditional transabdominal approach, improving accuracy of distal dissection and preservation of hypogastric innervation. An increasing interest on this new technique has raised, thanks to the excellent pathological and acceptable short-term clinical outcomes reported. Three consecutive cases of robotic transanal TME were prospectically performed between May 2017 and October 2017. TME quality was Quirke 3 grade in all cases. Mean operative time was 530 min. None of the patients had intra-operatively or post-operatively complications. Robotic transanal TME is a very recent procedure. Acclaimed greatest advantage of robotic transanal TME is the facilitation of dissection with an in-line view, which translates in an improved surgical field exposure and visualization. Further investigations are needed to assure the actual value of robotic transanal approach.

Sections du résumé

BACKGROUND BACKGROUND
Rectal cancer treatment is still a challenging frontier in general surgery, as there is no general agreement on which surgical approach is best for its management. Total mesorectal excision (TME), influenced the practical approach to rectal cancer, and brought a significant improvement on tumor recurrence and patients survival. Robotic transanal surgery is a newer approach to rectal dissection whose purpose is to overcome the limits of the traditional transabdominal approach, improving accuracy of distal dissection and preservation of hypogastric innervation. An increasing interest on this new technique has raised, thanks to the excellent pathological and acceptable short-term clinical outcomes reported.
MATERIALS AND METHODS METHODS
Three consecutive cases of robotic transanal TME were prospectically performed between May 2017 and October 2017.
RESULTS RESULTS
TME quality was Quirke 3 grade in all cases. Mean operative time was 530 min. None of the patients had intra-operatively or post-operatively complications.
CONCLUSIONS CONCLUSIONS
Robotic transanal TME is a very recent procedure. Acclaimed greatest advantage of robotic transanal TME is the facilitation of dissection with an in-line view, which translates in an improved surgical field exposure and visualization. Further investigations are needed to assure the actual value of robotic transanal approach.

Identifiants

pubmed: 31352319
pii: S2210-2612(19)30416-X
doi: 10.1016/j.ijscr.2019.07.034
pmc: PMC6664155
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

86-90

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Arch Surg. 1998 Aug;133(8):894-9
pubmed: 9711965
Surg Endosc. 2014 Dec;28(12):3494-9
pubmed: 24972923
Lancet. 1986 Jun 28;1(8496):1479-82
pubmed: 2425199
Colorectal Dis. 2018 Jun;20(6):O143-O151
pubmed: 29693307
Tech Coloproctol. 2016 Jan;20(1):71-3
pubmed: 26585960
Tech Coloproctol. 2014 Nov;18(11):1047-53
pubmed: 24957360
Ann Surg Oncol. 2016 Apr;23(4):1169-76
pubmed: 26597369
JAMA Surg. 2017 Apr 19;152(4):e165665
pubmed: 28196217
Lancet Oncol. 2013 Mar;14(3):210-8
pubmed: 23395398
Colorectal Dis. 2016 Jan;18(1):13-8
pubmed: 26400670
Lancet. 2005 May 14-20;365(9472):1718-26
pubmed: 15894098
Dis Colon Rectum. 1999 Jul;42(7):930-9
pubmed: 10411441
Ann Surg Oncol. 2010 Nov;17(11):2856-62
pubmed: 20567918
Int J Surg. 2018 Dec;60:279-282
pubmed: 30359781
Surg Endosc. 2019 Jun;33(6):1981-1987
pubmed: 30547391
Surg Endosc. 2013 Jun;27(6):1887-95
pubmed: 23292566
Tech Coloproctol. 2016 Aug;20(8):537-44
pubmed: 26993638
Updates Surg. 2019 Mar;71(1):29-37
pubmed: 30734896
Surg Endosc. 2010 Sep;24(9):2200-5
pubmed: 20174935
Surg Endosc. 2019 Jun;33(6):1858-1869
pubmed: 30251144

Auteurs

Igor Monsellato (I)

Division of General Surgery, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. Electronic address: igor.monsellato@ospedale.al.it.

Alessia Morello (A)

Division of General Surgery, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Marta Prati (M)

Division of General Surgery, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Giulio Argenio (G)

Division of General Surgery, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Domenico Piscioneri (D)

Division of General Surgery, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Luca Matteo Lenti (LM)

Division of General Surgery, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Fabio Priora (F)

Division of General Surgery, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Classifications MeSH